Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Inflammation 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1198Oxaliplatin 1160Capecitabine 1142Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Ashwagandha × Clear all
NCT05610735 2026-03-19

Combination Therapy for Recurrent Ovarian Cancer

University of Louisville

Phase 1/2 Recruiting
72 enrolled
Gynecologic

Ovarian Neoplasms

NCT04092647 2023-06-15

Ashwagandha for Cognitive Dysfunction

Sutter Health

Phase 2 Unknown
80 enrolled

Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction

NCT00817752 2010-03-18

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation

National University of Natural Medicine

Phase 1 Completed
25 enrolled

Autoimmune Diseases, Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡